Collecting samples from children with brainstem tumors
Official title: Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
Run by Children's National Research Institute · NCT01106794 · Data updated 2026-11-12
This study is trying to collect samples from children with brainstem tumors to see if they can find genetic clues that might help create better treatments for these tough cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 21 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Children's National Research Institute Academic / other |
| Locations | 1 site (Washington D.C., District of Columbia) |
| Status | Recruiting |
| Started | April 2010 |
| Main results expected | April 2025 |
| Study ends | April 2030 |
| Registry record updated | August 20, 2024 |
| Trial ID | NCT01106794 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include pediatric patients with a clinical and radiologic diagnosis of diffuse intrinsic pontine glioma or other high-grade gliomas originating in the brainstem.
✕Probably not a fit
Patients with low-grade gliomas or those with brainstem tumors of different histological types may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to prospectively gather specimens from pediatric patients diagnosed with diffuse intrinsic pontine glioma (DIPG) or brainstem glioma, either during their treatment or at the time of autopsy. The focus is on characterizing the molecular abnormalities associated with these tumors, which are known to be highly lethal and currently lack effective therapies. By analyzing various biological samples, including serum, cerebrospinal fluid, and tumor tissue, the study seeks to identify genetic markers that could lead to the development of targeted treatments for these aggressive cancers.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers and therapeutic targets for treating pediatric brainstem tumors.
How similar studies have gone: While this study focuses on a specific molecular analysis approach, similar studies have shown promise in identifying genetic abnormalities in other types of tumors, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of any age with clinical and radiologic diagnosis of diffuse intrinsic pontine glioma * Patients with other high-grade gliomas originating in the brainstem * Patients with focal gliomas (WHO grade I/II) of the brainstem Exclusion Criteria: * Patients with any type of infiltrative low grade (WHO grade I and II) or high grade glioma (WHO grade III and IV) originating outside the brainstem * Patients harboring primary brainstem tumors with other histologic diagnoses (e.g., PNET)
Where it's running
-
Children's National Medical Center
Washington D.C., District of Columbia, United States Recruiting
Study contacts
- Principal investigator: Javad Nazarian, PhD — Children's National Research Institute
- Study coordinator: Javad Nazarian, PhD
- Email: JNazarian@cnmc.org
- Phone: 202-476-6022
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
-
VRT106 plus radiotherapy in adults with DMG/DIPG
This trial tests whether adding VRT106 to radiotherapy is safe and could help adults with DMG/DIPG.
-
Combining Atovaquone with Radiation for Treating Children's Brain Tumors
This study is testing if adding atovaquone to radiation therapy can help children with aggressive brain tumors feel better and improve their treatment outcomes.
-
Eflornithine (DFMO) plus AMXT 1501 for neuroblastoma, CNS tumors, and sarcomas
This trial tests whether adding the oral drug AMXT 1501 to oral DFMO can help children and young adults (diagnosed by age 21) with relapsed or refractory neuroblastoma, ETMR, ATRT, Ewing sarcoma, osteosarcoma, or newly diagnosed DIPG.
-
Lorlatinib for newly diagnosed high-grade glioma with ALK or ROS1 fusions
This trial will test whether the oral medicine lorlatinib helps children and young adults (ages 1–21) with newly diagnosed high-grade gliomas that have ALK or ROS1 fusions, given alone, with chemotherapy, or after radiation.
-
Evaluating a new CAR T-cell therapy for children with DIPG
This study is testing a new CAR T-cell therapy to see if it can help children with DIPG fight their tumors after standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.